DENALI THERAPEUTICS INC (DNLI) Stock Fundamental Analysis

NASDAQ:DNLI • US24823R1059

18.77 USD
-0.41 (-2.14%)
At close: Feb 13, 2026
18.77 USD
0 (0%)
After Hours: 2/13/2026, 8:03:45 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall DNLI gets a fundamental rating of 2 out of 10. We evaluated DNLI against 523 industry peers in the Biotechnology industry. While DNLI seems to be doing ok healthwise, there are quite some concerns on its profitability. DNLI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • DNLI had negative earnings in the past year.
  • DNLI had a negative operating cash flow in the past year.
  • DNLI had negative earnings in 4 of the past 5 years.
  • In the past 5 years DNLI reported 4 times negative operating cash flow.
DNLI Yearly Net Income VS EBIT VS OCF VS FCFDNLI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M

1.2 Ratios

  • With a Return On Assets value of -41.07%, DNLI perfoms like the industry average, outperforming 58.13% of the companies in the same industry.
  • The Return On Equity of DNLI (-46.63%) is better than 67.88% of its industry peers.
Industry RankSector Rank
ROA -41.07%
ROE -46.63%
ROIC N/A
ROA(3y)-21.89%
ROA(5y)-16.39%
ROE(3y)-26.58%
ROE(5y)-20.75%
ROIC(3y)N/A
ROIC(5y)N/A
DNLI Yearly ROA, ROE, ROICDNLI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10 -20 -30 -40 -50

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for DNLI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DNLI Yearly Profit, Operating, Gross MarginsDNLI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • DNLI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • DNLI has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, DNLI has more shares outstanding
  • DNLI has a worse debt/assets ratio than last year.
DNLI Yearly Shares OutstandingDNLI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
DNLI Yearly Total Debt VS Total AssetsDNLI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • DNLI has an Altman-Z score of 9.33. This indicates that DNLI is financially healthy and has little risk of bankruptcy at the moment.
  • DNLI has a Altman-Z score of 9.33. This is amongst the best in the industry. DNLI outperforms 81.45% of its industry peers.
  • A Debt/Equity ratio of 0.01 indicates that DNLI is not too dependend on debt financing.
  • DNLI has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: DNLI outperforms 46.65% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 9.33
ROIC/WACCN/A
WACC12.25%
DNLI Yearly LT Debt VS Equity VS FCFDNLI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

  • A Current Ratio of 10.27 indicates that DNLI has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 10.27, DNLI belongs to the top of the industry, outperforming 82.22% of the companies in the same industry.
  • A Quick Ratio of 10.27 indicates that DNLI has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 10.27, DNLI belongs to the best of the industry, outperforming 82.22% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.27
Quick Ratio 10.27
DNLI Yearly Current Assets VS Current LiabilitesDNLI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • DNLI shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.75%.
  • DNLI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-1.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-17.46%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, DNLI will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.63% on average per year.
  • Based on estimates for the next years, DNLI will show a very strong growth in Revenue. The Revenue will grow by 133.17% on average per year.
EPS Next Y-14.15%
EPS Next 2Y-6.73%
EPS Next 3Y-1.03%
EPS Next 5Y11.63%
Revenue Next Year-87.68%
Revenue Next 2Y121.89%
Revenue Next 3Y165.09%
Revenue Next 5Y133.17%

3.3 Evolution

DNLI Yearly Revenue VS EstimatesDNLI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
DNLI Yearly EPS VS EstimatesDNLI Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1 2 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for DNLI. In the last year negative earnings were reported.
  • Also next year DNLI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DNLI Price Earnings VS Forward Price EarningsDNLI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DNLI Per share dataDNLI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.73%
EPS Next 3Y-1.03%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for DNLI!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DENALI THERAPEUTICS INC

NASDAQ:DNLI (2/13/2026, 8:03:45 PM)

After market: 18.77 0 (0%)

18.77

-0.41 (-2.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)02-25
Inst Owners91.98%
Inst Owner Change1.99%
Ins Owners4.28%
Ins Owner Change0.64%
Market Cap2.92B
Revenue(TTM)N/A
Net Income(TTM)-478.94M
Analysts88.33
Price Target32.55 (73.42%)
Short Float %11.32%
Short Ratio8.9
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.78%
Min EPS beat(2)-11.43%
Max EPS beat(2)1.88%
EPS beat(4)2
Avg EPS beat(4)2.05%
Min EPS beat(4)-11.43%
Max EPS beat(4)18.24%
EPS beat(8)4
Avg EPS beat(8)2.77%
EPS beat(12)6
Avg EPS beat(12)25.16%
EPS beat(16)7
Avg EPS beat(16)14.02%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)0
Avg Revenue beat(8)-98.61%
Revenue beat(12)2
Avg Revenue beat(12)97.93%
Revenue beat(16)4
Avg Revenue beat(16)68.59%
PT rev (1m)0.2%
PT rev (3m)-0.73%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-1.35%
EPS NY rev (3m)0.44%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)1400.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.68
P/tB 2.68
EV/EBITDA N/A
EPS(TTM)-2.91
EYN/A
EPS(NY)-3.04
Fwd EYN/A
FCF(TTM)-2.51
FCFYN/A
OCF(TTM)-2.38
OCFYN/A
SpS0
BVpS7
TBVpS7
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -41.07%
ROE -46.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-21.89%
ROA(5y)-16.39%
ROE(3y)-26.58%
ROE(5y)-20.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 152.73%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.27
Quick Ratio 10.27
Altman-Z 9.33
F-Score1
WACC12.25%
ROIC/WACCN/A
Cap/Depr(3y)141.82%
Cap/Depr(5y)112.16%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-17.46%
EPS Next Y-14.15%
EPS Next 2Y-6.73%
EPS Next 3Y-1.03%
EPS Next 5Y11.63%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-87.68%
Revenue Next 2Y121.89%
Revenue Next 3Y165.09%
Revenue Next 5Y133.17%
EBIT growth 1Y-7.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-8.08%
EBIT Next 3Y-2.68%
EBIT Next 5Y17.62%
FCF growth 1Y-14.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.93%
OCF growth 3YN/A
OCF growth 5YN/A

DENALI THERAPEUTICS INC / DNLI FAQ

What is the ChartMill fundamental rating of DENALI THERAPEUTICS INC (DNLI) stock?

ChartMill assigns a fundamental rating of 2 / 10 to DNLI.


Can you provide the valuation status for DENALI THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to DENALI THERAPEUTICS INC (DNLI). This can be considered as Overvalued.


How profitable is DENALI THERAPEUTICS INC (DNLI) stock?

DENALI THERAPEUTICS INC (DNLI) has a profitability rating of 1 / 10.


How financially healthy is DENALI THERAPEUTICS INC?

The financial health rating of DENALI THERAPEUTICS INC (DNLI) is 5 / 10.